GENE ONLINE|News &
Eisai and Biogen’s Alzheimer’s Med, Leqembi, Granted FDA Approval
On Saturday, the FDA announced it approved Eisai and Biogen’s jointly developed Alzheimer’s drug, Leqembi, under the accelerated approval program. The approval comes nearly two years after the regulatory agency approved the companies’ previous Alzheimer’s drug, Aduhelm, on the same accelerated pathway before it became the focal point of controversy in biotech. Alongside Leqembi’s accelerated approval, Eisai filed the drug’s supplemental Biologics License Application (sBLA) to gain traditional approval to provide wider access to the drug.
It's free! Log in now to read
LATEST
Iowa State University Researchers Link Primary Cilia to Temperature-Dependent Sex Determination in Turtles
2026-08-07
University of Illinois Study Finds Winter Canola Integration Increases Farm Profitability and Carbon Sequestration
2026-08-07
Southeast Farm and Forest Land Summit to Address Regional Development Pressures on October 12
2026-08-07
Rigoberto Advincula Named 2026 Fellow by American Chemical Society Industrial & Engineering Chemistry Division
2026-08-07
Study Finds Barbie and Ken Doll Proportions Have Shifted Toward Average Human Dimensions Over 30 Years
2026-08-07
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
